Phase II evaluation of anguidine in central nervous system tumors: a southwest Oncology Group study.
D000328:Adult; D000970:Antineoplastic Agents / Q000633:toxicity*; D001254:Astrocytoma / Q000188:drug therapy; D001932:Brain Neoplasms / Q000188:drug therapy*; D002528:Cerebellar Neoplasms / Q000188:drug therapy; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008527:Medulloblastoma / Q000188:drug therapy; D008875:Middle Aged; D009837:Oligodendroglioma / Q000188:drug therapy; D012717:Sesquiterpenes / Q000633:toxicity*; D014255:Trichothecenes / Q000627:therapeutic use / Q000633:toxicity*
D000970:Antineoplastic Agents; D012717:Sesquiterpenes; D014255:Trichothecenes; C001809:diacetoxyscirpenol